System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ricardo Canal-Bedia is an expert in Psychiatry at University of Salamanca (Spain). As of October 2026, ScienceLeadR ranks Ricardo Canal-Bedia in the top 1% of experts worldwide for Autism Spectrum Disorder and Child Development Disorders, Pervasive, and in the top 1% of experts in Spain for Autistic Disorder. Ricardo Canal-Bedia has authored 69 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 2 of them ongoing. SLR score: 239 (community average: 125). How the SLR is computed.

LeadR Profile

Ricardo Canal-Bedia University of Salamanca Spain
239 ScienceLeadR Reputation 239

Unlock

Register Login
Network Map

Psychiatry

Subspecialties: Psychology - Pediatrics - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1996 - 2026
Source: PubMed

University of Salamanca

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 69

Citations

Citations: 1 617 1st author: 5 Last author: 21 Unique author: 1

Main journals

J Autism Dev Disord 15
Rev Neurol 8
Neuroscience Applied 6
Front Psychiatry 4
Autism 3

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Acoustic Features, Parental Perception and Developmental Correlations of Crying in Preterm Infants: A Systematic Review and Meta-Analysis.
PMID 42435426 — acoustics, communication, infant, premature, perception, crying, colic, infant		Infancy20260
Costs of autism spectrum disorders and access to services in Spain.
PMID 42243945 — general practitioners, autism spectrum disorder, caregivers, autistic disorder, health services research, intellectual disability		BMC Health Serv Res20260
Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial.
PMID 41631164 — quality of life, safety, adolescent, child		EClinicalMedicine20260
An integrative approach between neurodiversity perspectives and quality of life models for autistic people across the spectrum of support needs.
PMID 41561984 — quality of life, language, autistic disorder, research		Front Psychiatry20260
Early social communication and language development in moderate-to-late preterm infants: a longitudinal study.
PMID 40248834 — language, longitudinal studies, communication, infant, premature, language development, infant		Front Psychol20250

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 2
Phase 2 1

By status:

Recruiting 2
Completed 1

By type:

Interventional 3

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 3
multicentricup10 0

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Follow Up Shiftability Study of Arbaclofen with an Open Label Extension for the study of Biomarkers for Treatment for Social Function in Children and Adolescents with Autism Spectrum Disorders
2023-508407-20-00 — autism spectrum disorder, biomarkers, autistic disorder, adolescent, therapeutics, child		Phase 3Recruiting2025
Single Dose Double blind Placebo controlled Cross over (SDDBPCCO) Shiftability Study Will be Followed by a 10 week Open label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active Stable Treatment) The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
NCT07655115 — autism spectrum disorder, biomarkers, autistic disorder, adolescent, therapeutics, child		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS